)
GeneDx (WGS) investor relations material
GeneDx AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Opening remarks and agenda
The meeting was held virtually to increase inclusivity and reach more stockholders.
Board members and officers present were introduced, including the CEO, CFO, and Chief Legal Officer.
The agenda included a business review and four formal proposals for stockholder voting.
Financial performance review
Reported $427.5 million in revenue for 2025, representing 41% year-over-year growth.
Achieved a 71% adjusted gross margin and $41.8 million in adjusted net income.
Received FDA Breakthrough Device designation for ExomeDx and GenomeDx tests.
Strategic initiatives and plans
Focused on expanding exome and genome testing utilization and optimizing unit economics.
Actively growing the core geneticist and pediatric specialist base and entering new markets.
Leveraging the SAVES-Kids study to demonstrate cost savings and strengthen payer relationships.
Exploring future opportunities in biopharma and data partnerships using the GeneDx Infinity platform.
- Expanding access to rare disease genomics with AI-driven tools and a unique data advantage.WGS
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Q1 revenue up 17% on strong test volume, but guidance lowered and net loss widened.WGS
Q1 20264 May 2026 - Annual meeting to vote on director, auditor, executive pay, and say-on-pay frequency, with board support.WGS
Proxy filing30 Apr 2026 - Key votes include director election, auditor ratification, and executive pay at the June 2026 meeting.WGS
Proxy filing30 Apr 2026 - 2026 guidance targets $540M–$555M revenue, 33%–35% test growth, and 71% gross margin.WGS
Q4 202511 Apr 2026 - Expanding genetic testing into new pediatric and prenatal markets with tailored sales and support.WGS
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Expanding genetic testing access and automation drives growth and profitability in rare disease care.WGS
Jefferies Global Healthcare Conference 20253 Feb 2026 - Q2 revenue up 52% YoY, gross margin at 62%, FY guidance raised, profitability expected 2025.WGS
Q2 20242 Feb 2026 - Epic integration and exome focus drive growth, margins, and data opportunities in rare disease.WGS
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
Next GeneDx earnings date
Next GeneDx earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)